Evidence map›Paper›PMID 40861785›Full record

ArticleInfection and drug resistance2025

Repurposing the Anticancer Drug Cisplatin for Antibacterial Therapy: Evaluating Its Efficacy Against

Hussam Daghistani, Dalya Attallah, Mona Abdulrahman Alqarni, Bandar Hasan Saleh, Nabeel H Alhussainy, Ahmad M Sait, Mohammed Mufrrih, Wafaa Alhazmi, Ohood S Alharbi, Khulud A Alhazmi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Busulfan inhibitsFrontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hussam DaghistaniDepartment of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Dalya AttallahDepartment of Clinical Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah, 21589, Saudi Arabia.ORCID 0009-0006-0082-1177
Mona Abdulrahman AlqarniDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Bandar Hasan SalehDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-3205-2986
Nabeel H AlhussainyDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Ahmad M SaitRegenerative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Mohammed MufrrihDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.ORCID 0000-0002-6834-2379
Wafaa AlhazmiDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.ORCID 0000-0001-5322-0953
Ohood S AlharbiDepartment of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.ORCID 0000-0002-8720-5054
Khulud A AlhazmiDepartment of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.ORCID 0009-0001-3980-1177
Rawan AltalhiDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, 23445, Saudi Arabia.
Waiel S HalabiDepartment of Optometry, Faculty of Applied Medical Sciences, University of Jeddah, Jeddah, 23218, Saudi Arabia.ORCID 0000-0002-6198-5566
Sarah AlmuhayyaDepartment of Clinical Laboratory Science, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Faye A AldehalanDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.ORCID 0000-0001-8553-1174
Hala AltarawnehDepartment of Microbiology and Pathology, Faculty of Medicine, Mutah University, Al-Karak, 61710, Jordan.
Mohammad Abu LubadDepartment of Microbiology and Pathology, Faculty of Medicine, Mutah University, Al-Karak, 61710, Jordan.
Sulaiman M S Bani Abdel-RahmanDepartment of Microbiology and Pathology, Faculty of Medicine, Mutah University, Al-Karak, 61710, Jordan.
Abdelbagi AlfadilDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0002-4070-6257
Karem IbrahemDepartment of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0009-0005-9473-3591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The rising global threat of antimicrobial resistance, particularly among multidrug-resistant pathogens like Methodology: This study assessed whether cisplatin could serve as a novel therapeutic option for treating infections caused by Results: The study found that 54.9% of isolates had an MIC of 16 µg/mL, 26.8% had 32 µg/mL, 12.7% had 64 µg/mL, and 5.6% had 8 µg/mL. While cisplatin demonstrated antibacterial activity, no statistically significant difference ( Conclusion: Although cisplatin exhibited activity against

Indexed as

antimicrobial resistancecisplatinMICPseudomonas aeruginosarepurposing drugs

Identifiers

PMID40861785
PMCPMC12374696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.